Crinetics Pharmaceuticals is a biotechnology business based in the US. Crinetics Pharmaceuticals shares (CRNX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $33.65 – an increase of 1.02% over the previous week. Crinetics Pharmaceuticals employs 437 staff and has a trailing 12-month revenue of around $1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $33.65 |
|---|---|
| 52-week range | $24.10 - $62.53 |
| 50-day moving average | $32.65 |
| 200-day moving average | $46.52 |
| Wall St. target price | $75.36 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.69 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $33.76 from 2025-05-02
| 1 week (2025-04-29) | 1.35% |
|---|---|
| 1 month (2025-04-07) | 27.98% |
| 3 months (2025-02-07) | -8.71% |
| 6 months (2024-11-07) | -43.55% |
| 1 year (2024-05-07) | -29.16% |
|---|---|
| 2 years (2023-05-05) | 51.05% |
| 3 years (2022-05-06) | 87.24% |
| 5 years (2020-05-06) | 76.20% |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $-239,116,992 |
| Return on assets TTM | -20.46% |
| Return on equity TTM | -32.02% |
| Profit margin | 0% |
| Book value | $14.26 |
| Market Capitalization | $3.1 billion |
TTM: trailing 12 months
We're not expecting Crinetics Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Crinetics Pharmaceuticals's shares have ranged in value from as little as $24.1 up to $62.53. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crinetics Pharmaceuticals's is 0.375. This would suggest that Crinetics Pharmaceuticals's shares are less volatile than average (for this exchange).
Crinetics Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co. , Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.